{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-26-000104","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2026-08-31T20:18:04+00:00","discovered_at":"2026-08-31T20:19:08.140767+00:00","generated_at":"2026-08-31T20:19:37.628573+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Federal Circuit affirms Exelixis patents; generic competitor blocked until Jan 15, 2030","bullets":["Court of Appeals affirmed validity of U.S. Patent Nos. 11,091,439, 11,091,440, 11,098,015.","FDA approval of MSN's ANDA effective no earlier than Jan 15, 2030, subject to appeals and exclusivity.","MSN's appeal on patent 11,298,349 dismissed as moot; that ruling vacated.","Separate litigation on patent 12,128,039 (expires Feb 2032) with trial set for Nov 2026.","Outcome protects Exelixis from generic competition until at least 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-26-000104","json":"https://secwatch.observer/filing/0000939767-26-000104.json","markdown":"https://secwatch.observer/filing/0000939767-26-000104.md","text":"https://secwatch.observer/filing/0000939767-26-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976726000104/0000939767-26-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976726000104/exel-20260831.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-31T20:19:37.628573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}